Published in Am J Pathol on February 08, 2013
Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol (2014) 0.99
Gene dosage-dependent negative regulatory role of β-arrestin-2 in polymicrobial infection-induced inflammation. Infect Immun (2013) 0.84
Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice. Lab Invest (2015) 0.81
β-Arrestin2 encourages inflammation-induced epithelial apoptosis through ER stress/PUMA in colitis. Mucosal Immunol (2014) 0.80
Nonhematopoietic β-Arrestin-1 inhibits inflammation in a murine model of polymicrobial sepsis. Am J Pathol (2014) 0.80
Regulation of macrophage biology by lithium: a new look at an old drug. J Neuroimmune Pharmacol (2013) 0.77
Endothelin-converting enzyme 1 and β-arrestins exert spatiotemporal control of substance P-induced inflammatory signals. J Biol Chem (2014) 0.77
Inflammation-induced abnormalities in the subcellular localization and trafficking of the neurokinin 1 receptor in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol (2015) 0.76
Protective Role of β-arrestin2 in Colitis Through Modulation of T-cell Activation. Inflamm Bowel Dis (2015) 0.76
Multifaceted role of β-arrestins in inflammation and disease. Genes Immun (2015) 0.75
Non-Hematopoietic β-Arrestin1 Confers Protection Against Experimental Colitis. J Cell Physiol (2015) 0.75
The emerging roles of β-arrestins in fibrotic diseases. Acta Pharmacol Sin (2015) 0.75
Protective effect of Lagerstroemia speciosa against dextran sulfate sodium induced ulcerative colitis in C57BL/6 mice. Am J Transl Res (2017) 0.75
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Inflammatory bowel disease. N Engl J Med (2002) 21.17
IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 14.99
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 9.16
Chemically induced mouse models of intestinal inflammation. Nat Protoc (2007) 8.65
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 4.94
Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med (2008) 4.68
Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology (1994) 4.57
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 3.52
T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med (2007) 3.29
MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol (2005) 3.02
Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med (2010) 2.82
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol (2010) 2.22
NF-kappaB in inflammatory bowel disease. J Intern Med (2008) 2.21
Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol (2005) 2.17
Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med (2010) 2.15
Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis (2007) 1.94
Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest (2003) 1.85
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis (2006) 1.71
Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J Biol Chem (2006) 1.45
Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res (2008) 1.37
Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology (2010) 1.33
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest (2008) 1.24
Animal models of inflammatory bowel disease. J Gastroenterol (2002) 1.23
The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol (1995) 1.21
Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn (1991) 1.17
Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994-2005. Am J Gastroenterol (2009) 1.16
Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol (2009) 1.13
Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol (2011) 1.11
Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins. J Cell Physiol (2010) 1.11
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis (2005) 1.10
An expanded family of arrestins regulate metabolism. Trends Endocrinol Metab (2012) 1.10
G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFκB activation in primary macrophages and modulates inflammation in vivo in mice. J Cell Physiol (2011) 1.07
β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med (2011) 1.06
Myeloid-specific GPCR kinase-2 negatively regulates NF-κB1p105-ERK pathway and limits endotoxemic shock in mice. J Cell Physiol (2011) 1.05
Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol (2005) 1.04
IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther (2002) 1.01
Increased expression of IL-16 in inflammatory bowel disease. Gut (2001) 1.00
Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol (1999) 0.98
Bone inflammation and altered gene expression with type I diabetes early onset. J Cell Physiol (2009) 0.97
Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients. Proc Natl Acad Sci U S A (1993) 0.95
Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: isoform specific regulation of inflammation. Mol Immunol (2011) 0.94
Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology (2006) 0.90
beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2. Virus Res (2009) 0.89
Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells. FASEB J (2007) 0.89
Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation (2006) 0.86
Loss of betaarrestin1 and betaarrestin2 contributes to pulmonary hypoplasia and neonatal lethality in mice. Dev Biol (2010) 0.83
Role of myeloid-specific G-protein coupled receptor kinase-2 in sepsis. Int J Clin Exp Med (2011) 0.80
IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation. Arch Immunol Ther Exp (Warsz) (2009) 0.76
A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J (2007) 2.72
Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem (2004) 2.32
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol (2002) 2.10
CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A (2006) 1.96
Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol (2008) 1.76
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology (2005) 1.70
Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell (2009) 1.67
CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology (2002) 1.62
Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology (2006) 1.57
Acute cobalt-induced lung injury and the role of hypoxia-inducible factor 1alpha in modulating inflammation. Toxicol Sci (2010) 1.53
Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab (2013) 1.45
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol (2005) 1.45
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A (2009) 1.43
Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg (2005) 1.39
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell (2009) 1.36
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol (2002) 1.34
Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science (2011) 1.30
G-protein-coupled-receptor kinases mediate TNFα-induced NFκB signalling via direct interaction with and phosphorylation of IκBα. Biochem J (2009) 1.25
Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem (2006) 1.24
Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol (2006) 1.22
Toll-like receptors differentially regulate GPCR kinases and arrestins in primary macrophages. Mol Immunol (2008) 1.20
Bone and glucose metabolism: a two-way street. Arch Biochem Biophys (2010) 1.18
Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest (2002) 1.17
MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res (2011) 1.12
Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins. J Cell Physiol (2010) 1.11
Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem (2004) 1.09
Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J Biol Chem (2003) 1.09
G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFκB activation in primary macrophages and modulates inflammation in vivo in mice. J Cell Physiol (2011) 1.07
Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol (2012) 1.05
From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle (2011) 1.05
Myeloid-specific GPCR kinase-2 negatively regulates NF-κB1p105-ERK pathway and limits endotoxemic shock in mice. J Cell Physiol (2011) 1.05
Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology (2006) 1.05
The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol (2011) 1.05
Streptozotocin, type I diabetes severity and bone. Biol Proced Online (2009) 1.04
The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem (2010) 1.04
Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J Cell Physiol (2013) 1.04
Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol (2011) 1.03
Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome. J Biol Chem (2010) 1.01
Type I diabetic bone phenotype is location but not gender dependent. Histochem Cell Biol (2007) 1.00
Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer (2003) 1.00
Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol (2014) 0.99
Effect of particle size on the dissolution behaviors of poorly water-soluble drugs. Arch Pharm Res (2012) 0.99
Bone inflammation and altered gene expression with type I diabetes early onset. J Cell Physiol (2009) 0.97
Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol (2009) 0.96
Osteoblasts respond to hydroxyapatite surfaces with immediate changes in gene expression. J Biomed Mater Res A (2004) 0.96
Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages. Mol Immunol (2007) 0.96
CCAAT/enhancer-binding protein-beta has a role in osteoblast proliferation and differentiation. Exp Cell Res (2004) 0.96
Reduced gap junctional intercellular communication and altered biological effects in mouse osteoblast and rat liver oval cell lines transfected with dominant-negative connexin 43. Mol Carcinog (2003) 0.95
Human bone marrow adiposity is linked with serum lipid levels not T1-diabetes. J Diabetes Complications (2012) 0.93
Highly tunable interfacial adhesion of glass fiber by hybrid multilayers of graphene oxide and aramid nanofiber. ACS Appl Mater Interfaces (2015) 0.93
Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.92
Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1. J Biol Chem (2005) 0.92
Simulated microgravity suppresses osteoblast phenotype, Runx2 levels and AP-1 transactivation. J Cell Biochem (2003) 0.92
MC3T3-E1 osteoblast attachment and proliferation on porous hydroxyapatite scaffolds fabricated with nanophase powder. Int J Nanomedicine (2006) 0.92
Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem (2002) 0.91
Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol (2012) 0.91
Par-4: a new activator of myosin phosphatase. Mol Biol Cell (2010) 0.91
Aberrant Huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res (2007) 0.90
beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2. Virus Res (2009) 0.89
Hypoxia suppresses runx2 independent of modeled microgravity. J Cell Physiol (2004) 0.89
Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage. Toxicol Sci (2009) 0.88
Calbindin-D28K prevents drug-induced dopaminergic neuronal death by inhibiting caspase and calpain activity. Biochem Biophys Res Commun (2008) 0.88
Finally, MALT1 is a protease! Nat Immunol (2008) 0.87
Cost-benefit analysis of the tsutsugamushi disease prevention program in South Korea. Jpn J Infect Dis (2012) 0.86
Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester. J Biol Chem (2002) 0.86
Economic burden of acute coronary syndrome in South Korea: a national survey. BMC Cardiovasc Disord (2013) 0.86
Reconstitution of CF IA from overexpressed subunits reveals stoichiometry and provides insights into molecular topology. Biochemistry (2011) 0.86
Gene dosage-dependent negative regulatory role of β-arrestin-2 in polymicrobial infection-induced inflammation. Infect Immun (2013) 0.84
Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci (2011) 0.84
Colitis-induced bone loss is gender dependent and associated with increased inflammation. Inflamm Bowel Dis (2013) 0.84
G-protein-coupled receptor kinase-5 mediates inflammation but does not regulate cellular infiltration or bacterial load in a polymicrobial sepsis model in mice. J Innate Immun (2013) 0.83
P38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose. J Biol Chem (2002) 0.83
Rabson-Mendenhall syndrome with recurrent cerebral infarcts caused by a novel INSR mutation. Int J Dermatol (2013) 0.83
Inhibition of cross-bridge formation has no effect on contraction-associated phosphorylation of p38 MAPK in mouse skeletal muscle. Am J Physiol Cell Physiol (2004) 0.83
Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity. J Cell Biochem (2011) 0.82
Investigation of polymeric excipients for dutasteride solid dispersion and its physicochemical characterization. Arch Pharm Res (2013) 0.81
CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. Am J Physiol Regul Integr Comp Physiol (2011) 0.81
Regulation of GPCR trafficking by RAMPs. Adv Exp Med Biol (2012) 0.80
Both spontaneous Ins2(+/-) and streptozotocin-induced type I diabetes cause bone loss in young mice. J Cell Physiol (2013) 0.80
Role of myeloid-specific G-protein coupled receptor kinase-2 in sepsis. Int J Clin Exp Med (2011) 0.80
Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. J Cell Physiol (2015) 0.79
Catheter related blood stream infections in the paediatric intensive care unit: A descriptive study. Indian J Crit Care Med (2013) 0.79
Mussel-inspired green synthesis of silver nanoparticles on graphene oxide nanosheets for enhanced catalytic applications. Chem Commun (Camb) (2013) 0.79
Overlapping and distinct roles of GRK5 in TLR2-, and TLR3-induced inflammatory response in vivo. Cell Immunol (2011) 0.79
A microengineered pathophysiological model of early-stage breast cancer. Lab Chip (2015) 0.79
Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity modifying protein-3. Am J Physiol Cell Physiol (2002) 0.78
Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance. Cell Rep (2012) 0.78
Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. Psychiatry Res (2010) 0.78
Enhanced production of early lineages of monocytic and granulocytic cells in mice with colitis. Proc Natl Acad Sci U S A (2012) 0.78
Regulation of Fc∈RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain. J Biol Chem (2014) 0.77
Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss. Cell Physiol Biochem (2011) 0.77